

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

# Innovent

信達生物製藥

**INNOVENT BIOLOGICS, INC.**

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1801)

## POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON JUNE 24, 2021

Reference is made to the circular (the “**Circular**”) of Innovent Biologics, Inc. (the “**Company**”) incorporating, amongst others, the notice (the “**Notice**”) of extraordinary general meeting of the Company (the “**EGM**”) dated June 8, 2021. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Circular.

At the EGM held on June 24, 2021, all the proposed resolutions as set out in the Notice were duly passed by way of poll and the poll results were as follows:

ORDINARY RESOLUTIONS		Number of Votes (%)	
		For	Against
1(a).	To approve and confirm the conditional grant of restricted shares to Dr. De-Chao Michael Yu (“ <b>Dr. Yu</b> ”) in accordance with the terms of the restricted share plan adopted by the Company on June 12, 2020 (the “ <b>2020 RS Plan</b> ”), subject to all applicable laws, rules, regulations and the applicable award agreement (the “ <b>Proposed Grant to Dr. Yu</b> ”)	493,817,229 70.837114%	203,299,302 29.162886%
1(b).	To authorize any one or more of the directors of the Company, with the exception of Dr. Yu, to exercise the powers of the Company to allot, issue and deal with the ordinary shares of the Company (the “ <b>Shares</b> ”) pursuant to the Proposed Grant to Dr. Yu under the specific mandate granted to the Directors by the shareholders of the Company (the “ <b>Shareholders</b> ”) at the extraordinary general meeting of the Company held on June 20, 2020 in accordance with the terms of the 2020 RS Plan (the “ <b>2020 RS Plan Specific Mandate</b> ”), such that the restricted shares shall rank <i>pari passu</i> in all respects among themselves and with the existing Shares in issue at the date of the allotment and issuance of the restricted shares, and that he/she/they be and is/are hereby authorized to take such actions, do such things, which in their opinion may be necessary, desirable or expedient for the purpose of giving effect to and/or to implement the transactions contemplated in 1(a) above	492,625,237 70.666125%	204,491,294 29.333875%

ORDINARY RESOLUTIONS		Number of Votes (%)	
		For	Against
2(a).	To approve and confirm the conditional grant of restricted shares to Mr. Ronald Hao Xi Ede (“ <b>Mr. Ede</b> ”) in accordance with the terms of 2020 RS Plan, subject to all applicable laws, rules, regulations and the applicable award agreement (the “ <b>Proposed Grant to Mr. Ede</b> ”)	493,817,229 70.836555%	203,304,802 29.163445%
2(b).	To authorize any one or more of the directors of the Company, with the exception of Mr. Ede, to exercise the powers of the Company to allot, issue and deal with the Shares pursuant to the Proposed Grant to Mr. Ede under the 2020 RS Plan Specific Mandate, such that the restricted shares shall rank <i>pari passu</i> in all respects among themselves and with the existing Shares in issue at the date of the allotment and issuance of the restricted shares, and that he/she/they be and is/are hereby authorized to take such actions, do such things, which in their opinion may be necessary, desirable or expedient for the purpose of giving effect to and/or to implement the transactions contemplated in 2(a) above;	492,625,237 70.665567%	204,496,794 29.334433%
3(a).	To approve and confirm the conditional grant of restricted shares to Dr. Charles Leland Cooney (“ <b>Dr. Cooney</b> ”) in accordance with the terms of 2020 RS Plan, subject to all applicable laws, rules, regulations and the applicable award agreement (the “ <b>Proposed Grant to Dr. Cooney</b> ”)	493,817,229 70.836555%	203,304,802 29.163445%
3(b).	To authorize any one or more of the directors of the Company, with the exception of Dr. Cooney, to exercise the powers of the Company to allot, issue and deal with the Shares pursuant to the Proposed Grant to Dr. Cooney under the 2020 RS Plan Specific Mandate, such that the restricted shares shall rank <i>pari passu</i> in all respects among themselves and with the existing Shares in issue at the date of the allotment and issuance of the restricted shares, and to take such actions, do such things, which in their opinion may be necessary, desirable or expedient for the purpose of giving effect to and/or to implement the transactions contemplated in 3(a) above	492,625,237 70.665567%	204,496,794 29.334433%

ORDINARY RESOLUTIONS		Number of Votes (%)	
		For	Against
4(a).	To approve and confirm the conditional grant of restricted shares to Ms. Joyce I-Yin Hsu (“ <b>Ms. Hsu</b> ”) in accordance with the terms of 2020 RS Plan, subject to all applicable laws, rules, regulations and the applicable award agreement (the “ <b>Proposed Grant to Ms. Hsu</b> ”)	493,817,229 70.836555%	203,304,802 29.163445%
4(b).	To authorize any one or more of the directors of the Company, with the exception of Ms. Hsu, to exercise the powers of the Company to allot, issue and deal with the Shares pursuant to the Proposed Grant to Ms. Hsu under the 2020 RS Plan Specific Mandate, such that the restricted shares shall rank <i>pari passu</i> in all respects among themselves and with the existing Shares in issue at the date of the allotment and issuance of the restricted shares, and that he/she/they be and is/are hereby authorized to take such actions, do such things, which in their opinion may be necessary, desirable or expedient for the purpose of giving effect to and/or to implement the transactions contemplated in 4(a) above;	492,625,237 70.665567%	204,496,794 29.334433%
5(a).	To approve and confirm the conditional grant of restricted shares to Dr. Kaixian Chen (“ <b>Dr. Chen</b> ”) in accordance with the terms of 2020 RS Plan, subject to all applicable laws, rules, regulations and the applicable award agreement (the “ <b>Proposed Grant to Dr. Chen</b> ”)	493,817,229 70.836555%	203,304,802 29.163445%
5(b).	To authorize any one or more of the directors of the Company, with the exception of Dr. Chen, to exercise the powers of the Company to allot, issue and deal with the Shares pursuant to the Proposed Grant to Dr. Chen under the 2020 RS Plan Specific Mandate, such that the restricted shares shall rank <i>pari passu</i> in all respects among themselves and with the existing Shares in issue at the date of the allotment and issuance of the restricted shares, and that and that he/she/they be and is/are hereby authorized to take such actions, do such things, which in their opinion may be necessary, desirable or expedient for the purpose of giving effect to and/or to implement the transactions contemplated in 5(a) above	492,625,237 70.664858%	204,503,794 29.335142%

By order of the Board  
**Innovent Biologics, Inc.**  
**Dr. De-Chao Michael Yu**  
*Chairman and Executive Director*

Hong Kong, June 24, 2021

*Notes:*

- (a) As at the date of the EGM, the total number of shares of the Company in issue was 1,457,846,747 shares.
- (b)
  - (i) As at the date of EGM, Dr. Yu and his associates, namely Gloria Bingqinzi Yu (as trustee of the Yu Tong Family Irrevocable Trust), are holding an aggregate of 103,139,190 shares of the Company. Dr. Yu and his associates were required to and had abstained from voting on the above proposed resolutions numbered 1(a) and 1(b) in relation to the Proposed Grant to Dr. Yu and transactions contemplated therein at the EGM in accordance with the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).
  - (ii) As at the date of EGM, Mr. Ede and his associates are holding an aggregate of 8,039,040 shares of the Company. Mr. Ede and his associates were required to and had abstained from voting on the above proposed resolutions numbered 2(a) and 2(b) in relation to the Proposed Grant to Mr. Ede and transactions contemplated therein at the EGM in accordance with the Listing Rules.
  - (iii) As at the date of EGM, Dr. Conney and his associates are holding an aggregate of 39,090 shares of the Company. Dr. Conney and his associates were required to and had abstained from voting on the above proposed resolutions numbered 3(a) and 3(b) in relation to the Proposed Grant to Dr. Cooney and transactions contemplated therein at the EGM in accordance with the Listing Rules.
- (c) Save as disclosed above, there were no shares entitling the holder to attend and abstain from voting in favour of the resolutions at the EGM as set out in rule 13.40 of the Listing Rules and no shareholders of the Company were required under the Listing Rules to abstain from voting on the resolutions proposed at the EGM. No parties have stated their intention in the Company’s Circular to vote against or to abstain from voting on any of the resolutions proposed at the EGM.
- (d) Accordingly, the total number of shares of the Company entitling the holders to attend and vote on the resolutions numbered 1(a) and 1(b) at the EGM was 1,354,707,557 shares; the total number of shares of the Company entitling the holders to attend and vote on the resolutions numbered 2(a) and 2(b) at the EGM was 1,449,807,707 shares; the total number of shares of the Company entitling the holders to attend and vote on the resolutions numbered 3(a) and 3(b) at the EGM was 1,457,807,657 shares.
- (e) The Company’s branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the vote-taking at the EGM.

*As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and Executive Director and Mr. Ronald Hao Xi Ede as Executive Director, Mr. Shuyun Chen as Non-executive Director, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu and Dr. Kaixian Chen as Independent Non-executive Directors.*